Is BIOAF or BTI a better dividend investment in 2026?

BIOAF currently yields 1000000.00% with a 5% 5-year dividend growth rate. BTI yields 5.38% with 5% growth. The better choice depends on your goal: BIOAF offers higher current income.

What is the dividend yield difference between BIOAF and BTI?

BIOAF has a forward dividend yield of 1000000.00% ($2.00/share annually). BTI yields 5.38% ($3.15/share annually). The yield gap is 999994.62 percentage points.

Home › Compare › BIOAF vs BTI

BIOAF vs BTI: Dividend Comparison 2026

BIOAF yields 1000000.00% · BTI yields 5.38%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 BIOAF wins by $4.7683925249533696e+36M in total portfolio value

INVESTMENT

TIME HORIZON10 years

BIOAF

● Live price

1000000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.7683925249533696e+36M

Annual income

$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00

Full BIOAF calculator →

BTI

● Live price

5.38%

Share price

$58.47

Annual div

$3.15

5Y div CAGR

11.3%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$37.7K

Annual income

$2,786.64

Full BTI calculator →

Portfolio growth — BIOAF vs BTI

📍 BIOAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	BIOAF	BTI
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, BIOAF + BTI cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

BIOAF pays

BTI pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BIOAF

Annual income on $10K today (after 15% tax)

$85,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr

BTI

Annual income on $10K today (after 15% tax)

$457.40/yr

After 10yr DRIP, annual income (after tax)

$2,368.64/yr

At 15% tax rate, BIOAF beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BIOAF + BTI for your $10,000?

BIOAF: 50%BTI: 50%

100% BTI50/50100% BIOAF

Portfolio after 10yr

$2.3841962624766848e+36M

Annual income

$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr

Blended yield

99.98%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

BIOAF

No analyst data

Altman Z

-42.0

Piotroski

2/9

BTI

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$40.00

-31.6% upside vs current

Range: $40.00 — $40.00

Altman Z

2.1

Piotroski

7/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BIOAF buys

BTI buys

No recent congressional trades found for BIOAF or BTI in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricBIOAFBTI

Forward yield	1000000.00% ✓	5.38%
Annual dividend / share	$2.00	$3.15 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	11.3% ✓
Portfolio after 10y	$4.7683925249533696e+36M	$37.7K ✓
Annual income after 10y	$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00 ✓	$2,786.64
Total dividends collected	$4.7683311610149396e+36M	$14.3K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Consumer Staples

Year-by-year: BIOAF vs BTI ($10,000, DRIP)

Year	BIOAF Portfolio	BIOAF Income/yr	BTI Portfolio	BTI Income/yr	Gap
1← crossover	$100,010,700	$100,000,000.00	$11,299	$598.92	+$100.00M → BIOAF
2	$934,786,450,701	$934,679,439,252.34	$12,794	$703.91	+$934786.44M → BIOAF
3	$8,165,787,108,578,292	$8,164,786,887,076,042.00	$14,518	$829.07	+$8165787108.56M → BIOAF
4	$66,665,884,190,957,650,000	$66,657,146,798,751,470,000.00	$16,513	$978.64	+$66665884190957.63M → BIOAF
5	$508,662,171,058,048,100,000,000	$508,590,838,561,963,700,000,000.00	$18,827	$1,157.84	+$508662171058048128.00M → BIOAF
6	$3,627,235,248,428,489,700,000,000,000	$3,626,690,979,905,457,600,000,000,000.00	$21,518	$1,373.12	+$3.62723524842849e+21M → BIOAF
7	$24,173,681,159,150,610,000,000,000,000,000	$24,169,800,017,434,790,000,000,000,000,000.00	$24,657	$1,632.46	+$2.417368115915061e+25M → BIOAF
8	$150,567,402,861,454,640,000,000,000,000,000,000	$150,541,537,022,614,370,000,000,000,000,000,000.00	$28,329	$1,945.74	+$1.5056740286145463e+29M → BIOAF
9	$876,477,100,281,847,600,000,000,000,000,000,000,000	$876,315,993,160,785,800,000,000,000,000,000,000,000.00	$32,637	$2,325.33	+$8.764771002818475e+32M → BIOAF
10	$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000	$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00	$37,708	$2,786.64	+$4.7683925249533696e+36M → BIOAF

BIOAF vs BTI: Complete Analysis 2026

BIOAF — Stock

Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.

Full BIOAF Calculator →

BTI — Consumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →

📬

Get this BIOAF vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BIOAF vs SCHD BIOAF vs JEPI BIOAF vs O BIOAF vs KO BIOAF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.